Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | BCL2 | P10415 | 2/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.42 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524665 | 0.89 | RPA1 (0.54) | RPA1MEN1KMT2AMDM2MCL1 | |
| SCHEMBL5522388 | 0.88 | CA9 (0.49) | RPA1 | |
| SCHEMBL2910437 | 0.87 | RPA1 (0.70) | RPA1MEN1KMT2AMDM2MCL1 | |
| SCHEMBL5524898 | 0.87 | SLC16A3 (0.40) | RPA1OXTR | |
| SCHEMBL2919104 | 0.86 | RPA1 (0.63) | RPA1MEN1KMT2AMDM2MCL1 | |
| SCHEMBL2915937 | 0.86 | RPA1 (0.63) | RPA1MEN1KMT2AMDM2MCL1 | |
| SCHEMBL2910507 | 0.85 | KMT2A (0.56) | RPA1MEN1KMT2AMDM2MCL1 | |
| SCHEMBL2919001 | 0.81 | SMN1; SMN2 (0.63) | RPA1MEN1KMT2AMDM2MCL1 | |
| SCHEMBL2911521 | 0.81 | RPA1 (0.70) | RPA1MDM2MCL1BCL2SMN1; SMN2 | |
| SCHEMBL5269886 | 0.81 | RPA1 (0.54) | RPA1MEN1KMT2AMDM2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | RPA1 1661/4885MEN1 2899/4885KMT2A 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.